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Introduction
Cardiovascular disease (CVD) is a highly prevalent com-
plication and the major cause of premature death in 
patients with type 2 diabetes mellitus (T2DM), with some 
estimates suggesting that 70%–75% of deaths may be 
attributable to cardiovascular (CV) complications.1–3 The 
current global diabetes epidemic combined with the 
increasing longevity of populations in most nations has 
led to a continued rise in the overall prevalence of CVD, 
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Abstract
Sulphonylureas (SUs) are widely used glucose-lowering agents in type 2 diabetes mellitus (T2DM) with apparent declining 
efficacy over time. Concerns have been raised from observational retrospective studies on the cardiovascular (CV) safety 
of SUs but there are few long-term data on CV outcomes from randomized controlled trials (RCTs) involving the use of 
this class of agents. Most of the observational studies and registry data are conflicting and vary with study population and 
methodology used for analyses. To address the SU controversy, we reviewed the recently published literature (until end 
of the year 2011) to evaluate the impact of SUs on CV outcomes in modern, longer-term (≥72 weeks) RCTs where they 
were compared in a head-to-head fashion versus an active comparator or were used as part of a treatment strategy. We 
identified 15 trials and found no report of an increase in the incidence of CV events with the use of SUs. However, the 
available data are limited, and, most importantly, there was no adequately powered formal head-to-head CV outcome 
trial designed to address CV safety. Since SUs are still being advocated as second-line therapy added-on to metformin, 
as one of several classes, and in certain circumstances first-line therapy in T2DM management, definitive data from a 
dedicated RCT addressing the CV safety question with SUs would be informative. Cardiovascular Outcome Study of 
Linagliptin versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA) is such a trial, ongoing since November 
2010, and is currently the largest head-to-head CV outcome trial that involves a comparison of a SU (glimepiride) with a 
dipeptidyl peptidase-4 (DPP-4) inhibitor (linagliptin) and will provide a unique perspective with respect to CV outcomes 
with these two commonly used agents.
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imposing an increasing burden on health-care systems.4,5 
Action to reduce this burden of diabetes-related CVD is 
therefore needed and includes the development of new 
and effective treatments for T2DM that may potentially 
benefit CV outcomes.
The last two decades have seen the development of a 
wide variety of new therapeutic options to treat the hyper-
glycaemia of T2DM. Each class of glucose-lowering 
agents can show broadly similar efficacy as monother-
apy with relatively minor and often non-clinically mean-
ingful differences in glucose-lowering potency (at least 
in short term), which depend in part on the study design 
populations and baseline glycated haemoglobin (HbA1c) 
levels.6 In contrast, each therapeutic class is character-
ized by a distinct adverse-event profile that may be 
related to the specific mechanism of action and/or poten-
tial off-target effects.7 Several of these side effects (in 
particular hypoglycaemia and weight gain) are clinically 
meaningful to patients and physicians, and it is conceiv-
able that these adverse events may further increase the 
CV risk in T2DM or may negate the potential CV benefits 
of some of the glucose-lowering agents.
Today, new diabetes agents face increased regulatory 
scrutiny and are required to demonstrate CV safety 
before, or after, approval. Indeed, the US Food and Drug 
Administration (FDA) key post-approval criterion to 
exclude unacceptable CVD risk for new diabetes drugs is 
an upper bound of the 95% confidence interval (CI) of 
<1.3 for the hazard ratio (HR) of CV events.8 On the other 
hand, these regulatory requirements may also provide the 
opportunity for some of the drugs in these ongoing CV 
outcome trials to be tested for CV benefits if the study 
design allows for sufficient statistical power. This review 
will cover the current evidence on the long-term risk of CV 
events with sulphonylureas (SUs), which remain one of the 
most widely used drug classes in T2DM. It will also review 
and put into a clinical perspective some of the currently 
ongoing CV studies of the dipeptidyl peptidase-4 (DPP-4) 
inhibitors, another class of glucose-lowering agents that 
are frequently added to metformin and that also stimulate 
insulin secretion, but are associated with a low risk of 
hypoglycaemia and do not result in weight gain.
Glycaemic control and CVD risk
Epidemiological studies have firmly established that the 
risk of CVD is progressively related to the degree of 
hyperglycaemia, as indicated by HbA1c levels.9,10 
However, despite the strong epidemiological association 
of HbA1c with CV events, there is less compelling evi-
dence that intervention studies designed to reduce glycae-
mia reduce the risk of CV events in patients with 
T2DM.11–13 The United Kingdom Prospective Diabetes 
Study (UKPDS) showed that a policy aiming for optimal 
glucose control using a SU or basal insulin was associated 
with a non-significant lower myocardial infarction (MI) 
risk versus standard therapy [relative risk (RR) = 0.84; 
95% CI = 0.71–1.00] after a median of 10 years of follow-
up, while the risk of deaths, stroke or amputation did not 
change significantly.14 Interestingly, the CV benefits of 
improved glycaemic control became evident only after an 
additional 10 years of follow-up after the end of the con-
trolled intervention component of the study as a ‘legacy 
effect’, during which time both groups were treated by 
their primary care physicians and achieved similar glu-
cose control.15 Clinically relevant post-trial RR reductions 
in MI (15%, p = 0.01) and death from any cause (13%, p 
= 0.007) emerged over this additional time, despite no sta-
tistically significant differences being observed in the 
interventional phase of the study. The results of the 
UKPDS therefore indicate that achieving optimal glucose 
control early in the course of T2DM in newly diagnosed 
patients could have long-term benefits, irrespective of 
treatment modality (SU, insulin or metformin). The 
Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) Trial16 demonstrated a non-significant reduc-
tion of 10% in the composite primary CV outcome of non-
fatal MI, non-fatal stroke and CV death among 10,251 
patients assigned to achieve a target HbA1c of <6.0%, 
versus those with a less challenging target of 7.0%–
7.9%.16 However, the intensive glucose-lowering compo-
nent of the trial was stopped early – after 3.5 years – due 
to an unexplained excess in all-cause mortality among 
patients receiving intensive therapy [257 deaths (5.0%)] 
vs 203 (4.0%) for standard therapy; HR = 1.22; 95% CI = 
1.01–1.46; p = 0.04]. Importantly, around one-third of 
patients in the study had experienced a previous CV event, 
and the authors suggested that intensive glucose-lowering 
therapy could be deleterious in patients with T2DM with 
a high risk of CVD. In addition, the intensive treatment 
group experienced significant weight gain and a clinically 
meaningful increased risk of severe hypoglycaemia,16 
which could have also contributed to the increased mor-
tality, although these possibilities remain controversial.
A lack of a beneficial effect on CVD outcomes of inten-
sive glycaemic management was also observed in two 
other large trials: the Action in Diabetes and Vascular 
Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation (ADVANCE) trial17 and the 
Veterans Affairs Diabetes Trial (VADT).18,19 These studies 
included patients with T2DM of moderate-to-long dura-
tion (mean duration at baseline, 8.0 and 11.5 years, respec-
tively) and, despite achieving significant differences in 
glucose control between the treatment arms, only non-
significant reductions in macrovascular events were 
observed.17,18 Together, UKPDS, ACCORD, ADVANCE 
and VADT provide interesting insights into the manage-
ment of CV risk in T2DM. The observed differences in 
outcomes between the UKPDS and the other studies could 
be related, at least in part, to differences in the study 
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populations. In the UKPDS, patients had newly diagnosed 
T2DM, whereas those in the other studies had more estab-
lished or advanced disease. Furthermore, in contrast to the 
UKPDS, ACCORD, ADVANCE and VADT, all recruited 
patients with increased CVD risk, about one-third of whom 
had a history of macrovascular disease compared with 
only 7.5% in the UKPDS.20 These differences in study 
populations could account for the relatively more favour-
able, potential and long-term ‘legacy effect’ of glycaemic 
control on CV outcomes observed in the UKPDS. The 
issue and hypothesis surrounding the ‘long-term legacy 
effect’ of glycaemic control are however in need of clarifi-
cation and will be further addressed with the post-trial 
monitoring implemented for ACCORD (ACCORDION – 
a prospective, observational follow-up study of at least 
8000 participants from ACCORD)21 and ADVANCE 
[ADVANCE-ON (NCT00949286) targeting 10,000 par-
ticipants from ADVANCE].22 Results from these two fol-
low-up studies are expected in the 2014–2015 timeframe.
Impact of specific diabetes 
therapies on CVD risk
A large number of diabetes drug classes are available for 
the management of T2DM, but it remains unclear how 
specific agents compare with respect to long-term CV 
risk.23,24 To date, the large CV outcome trials have essen-
tially assessed the impact of multiple combinations of 
glucose-lowering agents as part of an overall treatment 
regimen (e.g. UKPDS, ACCORD, ADVANCE and VADT) 
or as individual treatments versus placebo [e.g. the 
Prospective Pioglitazone Clinical Trial in Macrovascular 
Events (PROactive)25]. There have only been few,23,24 
long-term head-to-head trials that have compared the 
effects of different diabetes drugs on CV outcomes/CV 
surrogates [e.g. Carotid Intima–Media Thickness in 
Atherosclerosis Using Pioglitazone versus Glimepiride 
(CHICAGO),26 Pioglitazone Effect on Regression of 
Intravascular Sonographic Coronary Obstruction 
Prospective Evaluation (PERISCOPE)27 and Assessment 
on the Prevention of Progression by Rosiglitazone on 
Atherosclerosis in Type 2 Diabetes Patients with 
Cardiovascular History (APPROACH)28]. Thus, a com-
parative understanding of the CV impact of the most 
widely used diabetes drugs is for the most part lacking.13
Impact of SUs on CVD events in 
randomized controlled trials
SUs [e.g. glyburide (known as glibenclamide in Europe), 
gliclazide, glipizide or glimepiride] are frequently rec-
ommended as the preferred second-line therapy because of 
their well-established efficacy and low cost. However, the 
results of some studies have led to uncertainty about their 
durability and long-term CV safety, which may potentially 
be related to the fact that SUs not only bind to the SU 
receptor (SUR) subunit (subtype SUR1) of the potassium 
ATP (KATP) channel in the beta-cell membrane, but may 
also bind to the SUR receptor (subtype SUR2) on cardiac 
myocytes and on endothelial cells, and thus have direct 
effects on CV function.29
The controversy regarding the CV safety profile of 
SUs started with the highly criticized University Group 
Diabetes Program (UGDP), conducted in the 1960s that 
first gave rise to concerns about the safety of the first-
generation SU, tolbutamide. In this study, a significantly 
increased risk of all-cause and CV mortality was observed 
among participants receiving this SU versus placebo.30 
However, the UGDP was neither designed nor powered 
to test the hypothesis of inferior CV safety for SU versus 
placebo. The study has been criticized because the data 
were not corrected for the higher pre-existing CV risk in 
the SU-treated patients.31 Nevertheless, as a consequence 
of these data, every SU approved for use in the US has in 
its product label that SU use has been associated with 
increased CV mortality.
It is unclear whether the findings of the UGDP are appli-
cable to current clinical practice, where modern diabetes 
management includes a multifactorial approach to reduce 
the risk of CV complications.7 Furthermore, it is uncertain 
whether the UGDP findings apply to all SUs, as discussed 
in the following.
Table 1 lists 15 published randomized controlled trials 
(RCTs) (identified by searches in PubMed) reported over 
a 15-year period until the end of 2011 that were of ≥72-
week duration and included SU therapy versus an active 
comparator or as part of a treatment strategy (e.g. compar-
ing a diabetes treatment strategy to reach HbA1c ≤6.5% 
vs 7.5%). Because of the uncertain relevance of the UGDP 
trial findings to current day practice, and due to its initia-
tion more than 50 years ago, it is not included in Table 1. 
Retrospective cohort and observational studies are also 
excluded, with some discussed in the following. As listed 
in Table 1, the UKPDS demonstrated that chlorpropa-
mide, glyburide (glibenclamide) and glipizide were not 
associated with adverse CV events.14,15 The other 14 long-
term RCTs (Table 1), including A Diabetes Outcome 
Progression trial (ADOPT, n = 4360),32,33 also indicate 
that SUs were not associated with an increase in CVD risk 
when compared head-to-head trial with thiazolidinedi-
ones (glitazones), DPP-4 inhibitors, metformin or gluca-
gon-like peptide-1 (GLP-1) analogues.26–28,32–38 The same 
lack of an adverse outcome was observed when SUs were 
used as part of a treatment strategy to obtain different gly-
caemic targets,14–19,39–42 including the ADVANCE (n = 
11,140).17 However, it must be noted that none of the 
studies targeting ‘similar level’ of glycaemic control in 
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the treatment arms were powered to demonstrate CV 
safety/benefits, and there were inconsistencies in how the 
CVD events were reported and adjudicated. A recent 
meta-analysis of 40 RCTs of glucose-lowering agents 
found no increased risk of macrovascular events and all-
cause mortality with the use of second-generation SUs 
versus other oral agents or placebo.23 The authors made 
special note of the fact that most studies were not designed 
or powered to examine CV events, and that in addition to 
the lack of long-term studies, the poor quality and incon-
sistent reporting of adverse events in the published trials 
made it difficult to draw conclusions about the CV risk of 
commonly used diabetes medications.23 This conclusion 
also holds true for the studies listed in Table 1, and similar 
conclusion was reached by the Agency for Healthcare 
Research and Quality (AHRQ) in the more recent updated 
systematic review of the comparative effectiveness and 
safety of oral glucose-lowering medications for treating 
T2DM.24
Currently, data from recent longer-term RCT (Table 1) 
and observational studies44–48 remain discordant regard-
ing the CV safety of SUs. Several, but not all,49,50 obser-
vational studies have shown that all-cause and CV 
mortality are increased with either SU monotherapy44–47 
or when a SU is combined with metformin,47 as compared 
to metformin monotherapy. Furthermore, a meta-analysis 
of observational studies showed that SU–metformin 
combination therapy versus either monotherapy was 
associated with a significant increase in the RR of a com-
posite of CV hospitalization or mortality (overall RR = 
1.43; 95% CI = 1.10–1.85), but was not associated with a 
difference in either outcome alone that is difficult to 
explain.48 Recent RCTs versus two older RCTs also con-
flict. Apart from the aforementioned UGDP,30 a nested 
substudy of the UKPDS showed that the addition of met-
formin to a SU in obese and non-obese patients (n = 268) 
who were not reaching glycaemic targets was associated 
with an increased risk of diabetes-related death (96% 
increased risk, p = 0.039) and all-cause mortality (60% 
increase, p = 0.041) compared with SU monotherapy (n = 
296), which contradicts the parallel UKPDS report show-
ing CV benefits with metformin.43 However, the UKPDS 
investigators commented that these subgroup results 
might be a result of extremes of chance, and epidemio-
logical analysis of the possible association of death from 
diabetes-related causes showed no increased risk in 
patients treated with SU/metformin combination ther-
apy.43 To date, no follow-up results have been published 
on this study arm, and the findings of this substudy are 
also excluded from the summary in Table 1. In light of 
the discordant views about the safety of SUs (especially 
tolbutamide and chlorpropamide) and other glucose-low-
ering agents, there is clearly a need to explore the safety 
of these drugs in future trials.
New diabetes therapies and CVD 
risk: present studies involving DPP-
4 inhibitors
In response to concerns about the CV safety of diabetes 
drugs, at the end of 2008, the FDA issued a directive that 
clinical trials of new agents for the treatment of T2DM 
should demonstrate that new medications are not associated 
with an increased CV risk.8 The guidance also states that in 
order to obtain sufficient end points to allow a meaningful 
assessment of risk, studies should include patients at 
increased risk of CV events, such as those with relatively 
advanced disease, elderly patients and patients with some 
degree of renal impairment. Similar guidance has also been 
issued by the European Medicines Agency (EMA), which 
notes that the possibility of a relationship between some 
diabetes drugs and cardio/cerebrovascular disorders cannot 
be confirmed or excluded, and that the concerns raised by 
existing data require further in-depth evaluation.51
DPP-4 inhibitors are a newer class of oral agents for 
lowering of blood glucose and improve glycaemic control 
by inhibiting the inactivation of the incretin hormones, 
GLP-1 and glucose-dependent insulinotropic polypeptide.52 
These incretin hormones are short-lived intestinal peptides 
released in response to food ingestion, which have an inhib-
itory effect on glucagon (thereby reducing hepatic glucose 
synthesis) and an enhancing effect on insulin secretion, 
when glucose is elevated (not when it is normal or low). 
The first agent approved in this class (sitagliptin) was intro-
duced for clinical use in 2006. Of interest is that there are 
other physiological substrates of DPP-4 (e.g. stromal-
derived factor-1α – a chemokine that stimulates bone mar-
row mobilization of endothelial progenitor cells), which 
may or may not contribute to non-glycaemic effects of 
DPP-4 inhibitors, as discussed in the following section.
Three DPP-4 inhibitors, sitagliptin,53 saxagliptin54 and 
linagliptin,55 are currently available in the United States and 
elsewhere. A fourth inhibitor, vildagliptin,56 is available in 
Europe and other countries, but not in the United States, and 
a fifth inhibitor, alogliptin, is available in Japan.57 As a class, 
the DPP-4 inhibitors provide clinically meaningful reduc-
tions in HbA1c compared with placebo and convey a low 
risk of hypoglycaemia without weight gain.6
A range of potential CV benefits of DPP-4 inhibitors has 
been suggested based on findings from animal models, 
small proof-of-concept studies, and meta-analyses of clini-
cal studies. Data from the meta-analyses based on phase III 
trials published to date indicate that the use of some DPP-4 
inhibitors is associated with reductions in CV outcomes. 
Significant reductions were reported in a recent meta-anal-
ysis on linagliptin 5 mg (HR = 0.34; 95% CI = 0.16–0.70)58 
and in a previous analysis of saxagliptin 2.5–10 mg (HR = 
0.43; 95% CI = 0.23–0.80).59 In contrast, risk estimates 
were not significant for sitagliptin 100 mg (RR = 0.68; 95% 
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CI = 0.41–1.12),60 vildagliptin 50 and 100 mg (RR = 0.84; 
95% CI = 0.64–1.14 and RR = 0.88; 95% CI = 0.37–2.11, 
respectively)61 or alogliptin (HR = 0.61; 95% CI = 0.24–
1.56).62 How these possible benefits are mediated is not 
fully clear, but it would appear that both GLP-1 and non-
GLP-1-related pathways are involved that potentially 
improves endothelial function and inflammation and car-
diac function, reduces infarct size and atherosclerosis and 
enhances post-ischaemic recovery.52
Although the results of the different meta-analyses of 
DPP-4 inhibitors are not entirely comparable (due to dif-
ferences in primary composite end points and CV adjudi-
cation methods), all provide support to the hypothesis that 
DPP-4 inhibitor treatment may have a beneficial effect on 
CV outcome compared with other glucose-lowering treat-
ments for T2DM that need to be tested in RCTs. Indeed, 
there are several ongoing CV safety trials comparing dif-
ferent DPP-4 inhibitors versus placebo added to conven-
tional therapy in patients with T2DM who are at different 
stages of disease and receiving diverse glucose-lowering 
therapies.
These trials of DPP-4 inhibitors designed to evaluate 
CV outcomes in patients with T2DM are currently recruit-
ing or have recently completed recruitment of participants 
(Table 2). The Trial Evaluating Cardiovascular Outcomes 
with Sitagliptin (TECOS) is planned to last for 4–5 
years, with a projected completion date of December 
2014 (NCT00790205). A similar trial is the Saxagliptin 
Assessment of Vascular Outcomes Recorded in Patients 
with Diabetes Mellitus–Thrombolysis in Myocardial 
Infarction 53 (SAVOR-TIMI-53) trial, which will evaluate 
whether saxagliptin will reduce the risk of CV events when 
used alone, or added to other glucose-lowering therapies 
(NCT01107886).63 The Examination of Cardiovascular 
Outcomes: Alogliptin versus Standard Care in Patients 
with Type 2 Diabetes and Acute Coronary Syndrome 
(EXAMINE) trial will investigate the effect of alogliptin 
on CV outcomes in subjects with T2DM and acute coro-
nary syndrome. It will last for up to 4.75 years and is 
expected to be completed in May 2015 (NCT00968708).64 
Of note is that all of the aforementioned trials are placebo 
controlled when added to background therapy and thus 
cannot address the clinically relevant question of whether 
a DPP-4 inhibitor is a more suitable second-line therapy 
than a SU (Table 2). To gain the greatest possible insight 
into whether DPP-4 inhibitors hold advantages over 
other specific diabetes drugs in terms of CV outcomes, we 
believe it would be best to undertake head-to-head active 
comparator controlled trials. Such studies would largely 
extend our current knowledge, since existing data are 
mainly derived from post hoc pooled analyses of studies of 
limited duration.
The only such study to date is the ‘Cardiovascular 
Outcome Study of Linagliptin versus Glimepiride in Patients 
with Type 2 Diabetes’ (CAROLINA) (NCT01243424), 
which began in November 2010 and randomized patients 
with early T2DM and evidence of CVD or at high CV risk to 
linagliptin therapy versus glimepiride, predominantly as 
add-on to metformin background therapy. CAROLINA, 
which includes 6000 patients, is the first head-to-head CV 
outcome trial of a DPP-4 inhibitor versus an SU active com-
parator that is sufficiently powered to demonstrate differ-
ences in CV events. Its results may provide firm evidence to 
aid in the future clinical decision-making when selecting 
therapy in T2DM. Since in practice a proportion of patients 
with T2DM will have a renal contraindication or some 
degree of intolerance to metformin, and local guidelines 
may indicate other treatments as first-line therapy, the 
CAROLINA study also includes patients who are treatment-
naïve or on other monotherapies (SUs, meglitinides or 
α-glucosidase inhibitors).
Conclusion
Patients with T2DM are at a substantially increased risk of 
CVD compared with those without diabetes, and hypergly-
caemia is a well-established risk factor for CV events and 
mortality. The rationale for treatment of T2DM is to reduce 
hyperglycaemia and concomitantly reduce the risk of CV 
outcomes using a multifactorial interventional approach. 
However, several large glucose-lowering CV outcome 
studies have failed to show the benefits of glycaemic 
control on CV events and mortality.16–18
Overall, current evidence on the CV safety of diabetes 
drugs, and SUs in particular, remains inconclusive and 
somewhat controversial in light of discrepancies between 
RCTs and observational studies. There is, therefore, a 
need for properly designed, long-term, active controlled 
studies in T2DM to provide solid evidence on the poten-
tial benefit or lack thereof of different glucose-lowering 
therapies on CV events and mortality. Ongoing studies 
such as CAROLINA will provide important new informa-
tion on the CV safety of the DPP-4 inhibitor linagliptin 
versus the SU glimepiride and will contribute to the deci-
sion-making process for selecting the best evidence-based 
second-line therapy for addition to metformin in T2DM.
Key messages
•  Sulphonylureas (SUs) have been associated with 
increased cardiovascular (CV) risk, in particular CV 
mortality, as well as total mortality, in some observa-
tional studies and in two questionable randomized 
controlled trials (RCTs), that is, University Group 
Diabetes Program (UGDP) and a nested metformin 
added to SU versus SU alone substudy of the United 
Kingdom Prospective Diabetes Study (UKPDS).
 at GEORGE WASHINGTON UNIVERSITY on November 14, 2013dvr.sagepub.comDownloaded from 
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• In 15 well-designed longer-term (≥72 weeks) RCTs 
using SUs as part of a treatment strategy in type 2 dia-
betes mellitus (T2DM) [including Action in Diabetes 
and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE)] 
and from RCTs comparing SUs in a head-to-head 
fashion versus an active comparator [including A 
Diabetes Outcome Progression trial (ADOPT)], no 
CV safety signals were detected. However, the data 
are limited and CV events are inconsistently reported.
• Comparative effectiveness studies involving SUs are 
needed to determine whether SU therapy is linked to 
increased cardiovascular disease (CVD).
• The ongoing Cardiovascular Outcome Study of 
Linagliptin versus Glimepiride in Patients with Type 2 
Diabetes (CAROLINA) trial will provide unique 
insights into the CV safety profile of the SU glime-
piride versus the dipeptidyl peptidase (DPP-4) 
inhibitor linagliptin.
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